Class 1 recalls pose serious health risks, from undeclared allergens to bacterial contamination. Here’s how Class 1 recalls work, plus major FDA food recalls in 2025.

Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Britain's pharmacies regulator on Tuesday tightened rules for online pharmacies' prescribing obesity drugs, ordering them to make changes to prevent people from receiving drugs that could cause them ...

ResMed’s competitive edge is strong, but its current valuation seems inflated. Read why RMD stock might be ripe for ...

Kidney stone prevention centers around nutrition and lifestyle improvements. Learn what to eat, drink, avoid, and other ways ...

Obesity-drug maker Metsera Inc.'s stock jumped 47% on Friday as the biggest gainer among three initial public offerings bucking a swoon in the equity market to rise in their stock-market debuts Friday ...

Robert F. Kennedy Jr. sounded concern on the GRAS process and claimed GLP-1s are “miracle drugs” but fell short on the drugs ...